EVX-01
Evaxion Biotech
['melanoma']
$evax(1.48) up .70 trial in metastatic melanoma at the 2023 asco annual meeting in
chicago, illinois. the phase 1 trial successfully met primary endpoints for
safety and tolerability of evx-01 in metastatic melanoma patients and
demonstrated positive clinical responses in 8 out 
Very varied...trading stocks, futures, options, fishing, hunting, cooking, wanting to make a difference. All posts are for entertainment purposes only.